Toll-like receptors and chronic inflammation in rheumatic diseases: new developments

Nat Rev Rheumatol. 2016 Jun;12(6):344-57. doi: 10.1038/nrrheum.2016.61. Epub 2016 May 12.

Abstract

In the past few years, new developments have been reported on the role of Toll-like receptors (TLRs) in chronic inflammation in rheumatic diseases. The inhibitory function of TLR10 has been demonstrated. Receptors that enhance the function of TLRs, and several TLR inhibitors, have been identified. In addition, the role of the microbiome and TLRs in the onset of rheumatic diseases has been reported. We review novel insights on the role of TLRs in several inflammatory joint diseases, including rheumatoid arthritis, systemic lupus erythematosus, gout and Lyme arthritis, with a focus on the signalling mechanisms mediated by the Toll-IL-1 receptor (TIR) domain, the exogenous and endogenous ligands of TLRs, and the current and future therapeutic strategies to target TLR signalling in rheumatic diseases.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Neutralizing / therapeutic use
  • Humans
  • Inflammation / immunology*
  • Molecular Targeted Therapy
  • Receptors, Interleukin-1 / immunology*
  • Rheumatic Diseases / drug therapy
  • Rheumatic Diseases / immunology*
  • Toll-Like Receptors / antagonists & inhibitors
  • Toll-Like Receptors / immunology*

Substances

  • Antibodies, Neutralizing
  • Receptors, Interleukin-1
  • Toll-Like Receptors